In this episode, the experts discuss the latest insights on osimertinib resistance in EGFR-mutated NSCLC and promising new data on targeting MET amplification, one of the most common acquired resistance mechanisms to first-line osimertinib.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
